Table 3.
The characteristics related to management of CIP stratified by grade of CIP.
| Grade of CIP Mean ± SD/N (%) | Total | Grade 2 | Grade 3 | Grade 4 | P-value |
|---|---|---|---|---|---|
| N | 44 | 18 | 19 | 7 | |
| Steroid initial dose (mg/d) | 425.29 ± 451.82 | 280.40 ± 411.75 | 527.56 ± 469.29 | 360.00 ± 554.26 | 0.426 |
| Steroid initial dose groups (mg/d) | 0.379 | ||||
| Low-dose <60 | 5 (29.41%) | 1 (20.00%) | 2 (22.22%) | 2 (66.67%) | |
| Intermediate-dose 60-500 | 6 (35.29%) | 3 (60.00%) | 3 (33.33%) | 0 (0.00%) | |
| High-dose 501-1000 | 6 (35.29%) | 1 (20.00%) | 4 (44.44%) | 1 (33.33%) | |
| Steroid initial dose (mg/kg/d) | 1.24 ± 0.58 | 0.86 ± 0.10 | 2.00 ± 0.40 | 2.00 ± 0.00 | <0.001 |
| Steroid initial dose groups (mg/kg/d) | 0.007 | ||||
| Low-dose <1 | 8 (53.33%) | 8 (80.00%) | 0 (0.00%) | 0 (0.00%) | |
| Intermediate-dose 1-2 | 6 (40.00%) | 2 (20.00%) | 2 (66.67%) | 2 (100.00%) | |
| High-dose >2 | 1 (6.67%) | 0 (0.00%) | 1 (33.33%) | 0 (0.00%) | |
| Steroid taper time | 10.46 ± 9.94 | 7.20 ± 5.35 | 16.37 ± 14.60 | 8.25 ± 4.79 | 0.154 |
| Steroid course | 14.43 ± 15.14 | 12.23 ± 8.54 | 16.35 ± 20.75 | 15.62 ± 14.75 | 0.776 |
| Immunosuppressive drugs | 0.016 | ||||
| No | 35 (79.55%) | 17 (94.44%) | 15 (78.95%) | 3 (42.86%) | |
| Yes | 9 (20.45%) | 1 (5.56%) | 4 (21.05%) | 4 (57.14%) | |
| Antibiotics | 0.011 | ||||
| No | 28 (63.64%) | 14 (77.78%) | 13 (68.42%) | 1 (14.29%) | |
| Yes | 16 (36.36%) | 4 (22.22%) | 6 (31.58%) | 6 (85.71%) | |
| Recurrent times | 0.312 | ||||
| 0 | 34 (77.27% | 14 (77.78%) | 14 (73.68%) | 6 (85.71%) | |
| 1 | 6 (13.64%) | 4 (22.22%) | 2 (10.53%) | 0 (0.00%) | |
| 2 | 2 (4.55%) | 0 (0.00%) | 2 (10.53%) | 0 (0.00%) | |
| 3 | 2 (4.55%) | 0 (0.00%) | 1 (5.26%) | 1 (14.29%) | |
| CIP outcome | 0.003 | ||||
| Improved/Resolved | 34 (77.27%) | 18 (100.00%) | 13 (68.42%) | 3 (42.86%) | |
| Deteriorated/Maintained | 10 (22.73%) | 0 (0.00%) | 6 (31.58%) | 4 (57.14%) | |
| CIP course (weeks) | 12.64 ± 14.20 | 10.30 ± 7.90 | 14.85 ± 19.20 | 12.96 ± 13.09 | 0.673 |
| OS | 0.019 | ||||
| Alive | 20 (57.14%) | 12 (85.71%) | 5 (35.71%) | 3 (42.86%) | |
| Dead | 15 (42.86%) | 2 (14.29%) | 9 (64.29%) | 4 (57.14%) | |
| Survival time (weeks) | 55.35 ± 46.26 | 72.92 ± 58.13 | 41.00 ± 29.64 | 46.00 ± 37.33 | 0.198 |
| Clinical response | 0.018 | ||||
| Complete response | 2 (5.71%) | 0 (0.00%) | 2 (14.29%) | 0 (0.00%) | |
| Partial response | 6 (17.14%) | 6 (42.86%) | 0 (0.00%) | 0 (0.00%) | |
| Tumor progressed | 5 (14.29%) | 2 (14.29%) | 2 (14.29%) | 1 (14.29%) | |
| Stable | 7 (20.00%) | 4 (28.57%) | 1 (7.14%) | 2 (28.57%) | |
| Unknown | 15 (42.86%) | 2 (14.29%) | 9 (64.29%) | 4 (57.14%) |
CIP, checkpoint inhibitor pneumonitis; OS, overall survival.
Bold values: two-sided P-values less than 0.05 were considered to identify statistical significance.